Cravath’s London Office Moves to 100 Cheapside
Alexander Gerten focuses his practice on financial restructuring and reorganization matters, including debtor and creditor representations, related financings and distressed M&A.
Mr. Gerten serves as Secretary of the New York City Bar Association’s Bankruptcy and Corporate Reorganization Committee.
Mr. Gerten was born in Saint Paul, Minnesota. He received a B.S. with distinction from the University of Wisconsin in 2012 and a J.D. from Columbia in 2016, where he was a Harlan Fiske Stone Scholar.
Mr. Gerten joined Cravath in 2016 and departed in 2021. He rejoined Cravath in 2022 and was named of counsel in 2024.
Mr. Gerten serves as Secretary of the New York City Bar Association’s Bankruptcy and Corporate Reorganization Committee.
Mr. Gerten was born in Saint Paul, Minnesota. He received a B.S. with distinction from the University of Wisconsin in 2012 and a J.D. from Columbia in 2016, where he was a Harlan Fiske Stone Scholar.
Mr. Gerten joined Cravath in 2016 and departed in 2021. He rejoined Cravath in 2022 and was named of counsel in 2024.
Education
-
J.D., 2016, Columbia Law SchoolHarlan Fiske Stone Scholar
-
B.S., 2012, University of Wisconsin - MadisonGraduated with Distinction; Stone Scholarship in Economics
Admitted In
- New York
Professional Affiliations
New York City Bar Association
- Secretary, Bankruptcy & Corporate Reorganization Committee
Deals & Cases
October 04, 2024
DRI Healthcare Trust’s Acquisition of Payment Streams Based on the Cas9 Gene‑Editing Technology for CASGEVY®
On October 3, 2024, DRI Healthcare Trust, a global leader in providing financing to advance innovation in the life sciences industry, announced that one of its wholly owned subsidiaries acquired a portion of Editas Medicine, Inc.'s payment rights under a non‑exclusive license of Editas' Cas9 gene‑editing technology for CASGEVY®, the only approved gene‑edited cell therapy for sickle cell disease and transfusion‑dependent beta thalassemia, for an upfront purchase price of $57 million. The transaction entitles DRI Healthcare to specific payments based on a sublicensing agreement between Editas and Vertex Pharmaceuticals Incorporated. The payments include a share of the annual license fees that Vertex pays to Editas, which can range from $5 million to $40 million, including certain sales‑based annual license fee increases, and a portion of a $50 million contingent payment to which Editas is eligible under the Vertex sublicensing agreement. Cravath is representing DRI Healthcare in connection with the transaction.
Deals & Cases
February 28, 2024
Viatris’s Global Research and Development Collaboration with Idorsia
On February 28, 2024, Viatris Inc. (“Viatris”), a global healthcare company, and Idorsia Ltd (“Idorsia”) announced they have entered into agreements for a significant global research and development collaboration under which Viatris will receive exclusive global development and commercialization rights to two Phase 3 assets as well as the potential to add additional innovative assets in the future.
Deals & Cases
August 15, 2023
DRI Healthcare Trust’s Acquisition of a Second Royalty Interest in the Worldwide Sales of ORSERDU®
On August 14, 2023, DRI Healthcare Trust, a global leader in providing financing to advance innovation in the life sciences industry, managed by DRI Capital Inc., announced that it has purchased a second royalty interest in the worldwide net sales of ORSERDU®, the first approved targeted therapy used in the treatment of postmenopausal women or adult men with advanced or metastatic breast cancer who have experienced disease progression despite prior endocrine therapy. DRI Healthcare entered into a purchase agreement with Radius Pharmaceuticals, Inc., a wholly owned subsidiary of Radius Health, Inc. for an upfront purchase price of $130 million. In addition to running royalties, DRI Healthcare is also entitled to receive milestone payments of up to $40 million on the achievement of sales performance thresholds. Cravath represented DRI Capital Inc. in connection with the transaction.
Firm News
June 28, 2024
Cravath Announces New Partner, European Counsels and Of Counsels
Cravath has elected the following new partner, who will become a member of the Firm on July 1, 2024:
Alexander Gerten focuses his practice on financial restructuring and reorganization matters, including debtor and creditor representations, related financings and distressed M&A.
Mr. Gerten serves as Secretary of the New York City Bar Association’s Bankruptcy and Corporate Reorganization Committee.
Mr. Gerten was born in Saint Paul, Minnesota. He received a B.S. with distinction from the University of Wisconsin in 2012 and a J.D. from Columbia in 2016, where he was a Harlan Fiske Stone Scholar.
Mr. Gerten joined Cravath in 2016 and departed in 2021. He rejoined Cravath in 2022 and was named of counsel in 2024.
Mr. Gerten serves as Secretary of the New York City Bar Association’s Bankruptcy and Corporate Reorganization Committee.
Mr. Gerten was born in Saint Paul, Minnesota. He received a B.S. with distinction from the University of Wisconsin in 2012 and a J.D. from Columbia in 2016, where he was a Harlan Fiske Stone Scholar.
Mr. Gerten joined Cravath in 2016 and departed in 2021. He rejoined Cravath in 2022 and was named of counsel in 2024.
Education
-
J.D., 2016, Columbia Law SchoolHarlan Fiske Stone Scholar
-
B.S., 2012, University of Wisconsin - MadisonGraduated with Distinction; Stone Scholarship in Economics
Admitted In
- New York
Professional Affiliations
New York City Bar Association
- Secretary, Bankruptcy & Corporate Reorganization Committee
Deals & Cases
October 04, 2024
DRI Healthcare Trust’s Acquisition of Payment Streams Based on the Cas9 Gene‑Editing Technology for CASGEVY®
On October 3, 2024, DRI Healthcare Trust, a global leader in providing financing to advance innovation in the life sciences industry, announced that one of its wholly owned subsidiaries acquired a portion of Editas Medicine, Inc.'s payment rights under a non‑exclusive license of Editas' Cas9 gene‑editing technology for CASGEVY®, the only approved gene‑edited cell therapy for sickle cell disease and transfusion‑dependent beta thalassemia, for an upfront purchase price of $57 million. The transaction entitles DRI Healthcare to specific payments based on a sublicensing agreement between Editas and Vertex Pharmaceuticals Incorporated. The payments include a share of the annual license fees that Vertex pays to Editas, which can range from $5 million to $40 million, including certain sales‑based annual license fee increases, and a portion of a $50 million contingent payment to which Editas is eligible under the Vertex sublicensing agreement. Cravath is representing DRI Healthcare in connection with the transaction.
Deals & Cases
February 28, 2024
Viatris’s Global Research and Development Collaboration with Idorsia
On February 28, 2024, Viatris Inc. (“Viatris”), a global healthcare company, and Idorsia Ltd (“Idorsia”) announced they have entered into agreements for a significant global research and development collaboration under which Viatris will receive exclusive global development and commercialization rights to two Phase 3 assets as well as the potential to add additional innovative assets in the future.
Deals & Cases
August 15, 2023
DRI Healthcare Trust’s Acquisition of a Second Royalty Interest in the Worldwide Sales of ORSERDU®
On August 14, 2023, DRI Healthcare Trust, a global leader in providing financing to advance innovation in the life sciences industry, managed by DRI Capital Inc., announced that it has purchased a second royalty interest in the worldwide net sales of ORSERDU®, the first approved targeted therapy used in the treatment of postmenopausal women or adult men with advanced or metastatic breast cancer who have experienced disease progression despite prior endocrine therapy. DRI Healthcare entered into a purchase agreement with Radius Pharmaceuticals, Inc., a wholly owned subsidiary of Radius Health, Inc. for an upfront purchase price of $130 million. In addition to running royalties, DRI Healthcare is also entitled to receive milestone payments of up to $40 million on the achievement of sales performance thresholds. Cravath represented DRI Capital Inc. in connection with the transaction.
Firm News
June 28, 2024
Cravath Announces New Partner, European Counsels and Of Counsels
Cravath has elected the following new partner, who will become a member of the Firm on July 1, 2024:
Cravath Bicentennial
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2025 Cravath, Swaine & Moore LLP.